Genetic‐Guided Pharmacotherapy for Coronary Artery Disease: A Systematic and Critical Review of Economic Evaluations
KK Lim, R Koleva‐Kolarova… - Journal of the …, 2024 - Am Heart Assoc
Background Genetic‐guided pharmacotherapy (PGx) is not recommended in clinical
guidelines for coronary artery disease (CAD). We aimed to examine the extent and quality of …
guidelines for coronary artery disease (CAD). We aimed to examine the extent and quality of …
A Comparison of the Content and Consistency of Methodological Quality and Transferability Checklists for Reviewing Model-Based Economic Evaluations
KK Lim, R Koleva-Kolarova, J Fox-Rushby - PharmacoEconomics, 2022 - Springer
Objectives The aim of this study was to examine whether and how the content of six
checklists (Caro, Consensus on Health Economic Criteria [CHEC]-Extended, European …
checklists (Caro, Consensus on Health Economic Criteria [CHEC]-Extended, European …
Development of an optimized and generic cost-utility model for analyzing genome-guided treatment data
Economic evaluation is an integral component of informed public health decision-making in
personalized medicine. However, performing economic evaluation assessments often …
personalized medicine. However, performing economic evaluation assessments often …
[HTML][HTML] Genetic-guided pharmacotherapy for atrial fibrillation: a systematic and critical review of economic evaluations
AA Kamil, KK Lim, R Koleva-Kolarova, P Chowienczyk… - Value in Health, 2022 - Elsevier
Objectives This study aimed to examine the extent and quality of evidence from economic
evaluations (EEs) of genetic-guided pharmacotherapy (PGx) for atrial fibrillation (AF) and to …
evaluations (EEs) of genetic-guided pharmacotherapy (PGx) for atrial fibrillation (AF) and to …